These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The influence of atropine on the cardiopulmonary effects of a xylazine-ketamine combination in dogs.
    Author: Magoon KE, Hsu WH, Hembrough FB.
    Journal: Arch Int Pharmacodyn Ther; 1988; 293():143-53. PubMed ID: 3421774.
    Abstract:
    The effect of atropine on cardiopulmonary changes induced by xylazine-ketamine anesthesia was studied in 7 male dogs. A consecutive i.v. injection of xylazine (1.1 mg/kg) and ketamine (11 mg/kg) induced an anesthesia of approximately 20 min, and increased PaCO2 but decreased PaO2 and pHa for 20 min. The xylazine-ketamine administration increased heart rate for 5 min, which was followed by a small but significant decrease at 30 min posttreatment. The xylazine-ketamine injection decreased left ventricular and mean aortic pressure for 1 to 2 min. The low pressures returned to normal and became higher than base line levels at 5 min posttreatment. The xylazine-ketamine injection increased peripheral resistance and decreased cardiac output and cardiac index for at least 40 min. An i.v. injection of atropine sulfate (0.04 mg/kg) potentiated the effect of xylazine-ketamine on PaCO2 and PaO2, but did not change the effect of xylazine-ketamine on pHa. The atropine injection did not change the transient low left ventricular and mean aortic pressures immediate after the xylazine-ketamine administration, but did potentiate the duration of the increased heart rate, left ventricular and mean aortic pressures induced by xylazine-ketamine between 5 to 40 min. Atropine did not change the effect of xylazine-ketamine on peripheral resistance. Atropine partially antagonized the effect of xylazine-ketamine on cardiac output and cardiac index. Interpretation of the results indicates that atropine may increase cardiac work and may potentiate the pulmonary effect of i.v. administration of xylazine-ketamine.
    [Abstract] [Full Text] [Related] [New Search]